Thomas Jefferson University

Jefferson Digital Commons
Abington Jefferson Health Papers

Abington Jefferson Health

11-26-2020

Effects of left ventricular assist device on pulmonary functions
and pulmonary hemodynamics: A meta-analysis
Waqas Ullah
Abington Jefferson Health

Casey Meizinger
Abington Jefferson Health

Zain Ali
Abington Jefferson Health

Ankur Panchal
University of Pittsburgh

Rehan Saeed
Abington Jefferson Health
Follow this and additional works at: https://jdc.jefferson.edu/abingtonfp
Part of the Cardiology Commons, and the Internal Medicine Commons
See next page for additional authors

Let us know how access to this document benefits you
Recommended Citation
Ullah, Waqas; Meizinger, Casey; Ali, Zain; Panchal, Ankur; Saeed, Rehan; Haas, Donald C.; and
Rame, Eduardo, "Effects of left ventricular assist device on pulmonary functions and pulmonary
hemodynamics: A meta-analysis" (2020). Abington Jefferson Health Papers. Paper 56.
https://jdc.jefferson.edu/abingtonfp/56
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Abington Jefferson Health Papers by an authorized administrator of the Jefferson Digital
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Waqas Ullah, Casey Meizinger, Zain Ali, Ankur Panchal, Rehan Saeed, Donald C. Haas, and Eduardo Rame

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/abingtonfp/56

ISSN 1949-8462 (online)

World Journal of
Cardiology
World J Cardiol 2020 November 26; 12(11): 513-598

Published by Baishideng Publishing Group Inc

WJ C
Contents

World Journal of
Cardiology
Monthly Volume 12 Number 11 November 26, 2020

ORIGINAL ARTICLE
Retrospective Study
513

Effectiveness and safety of antithrombotic strategies in elderly patients with acute myocardial infarction
Rondano E, Bertolazzi M, Galluzzo A, Maltese L, Caccianotti P, Macciò S, Mazza S, Di Ruocco MV, Favretto S, Occhetta E,
Rametta F

Clinical Trials Study
526

Endothelial progenitor cells mobilization after maximal exercise according to heart failure severity
Kourek C, Karatzanos E, Psarra K, Georgiopoulos G, Delis D, Linardatou V, Gavrielatos G, Papadopoulos C, Nanas S,
Dimopoulos S

SYSTEMATIC REVIEWS
540

Rapid right ventricular pacing for balloon valvuloplasty in congenital aortic stenosis: A systematic review
Mylonas KS, Ziogas IA, Mylona CS, Avgerinos DV, Bakoyiannis C, Mitropoulos F, Tzifa A

META-ANALYSIS
550

Effects of left ventricular assist device on pulmonary functions and pulmonary hemodynamics: A metaanalysis
Ullah W, Meizinger C, Ali Z, Panchal A, Saeed R, Haas DC, Rame E

559

Medical therapy vs early revascularization in diabetics with chronic total occlusions: A meta-analysis and
systematic review
Khan MS, Sami FA, Singh H, Ullah W, Al-Dabbas M, Changal KH, Mir T, Ali Z, Kabour A

571

Transradial vs transfemoral secondary access outcomes in transcatheter aortic valve implantation: A
systematic review and meta-analysis
Radhakrishnan SL, Ho KKL

584

Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and
meta-analysis
Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S,
Gullapalli N

WJC

https://www.wjgnet.com

I

November 26, 2020

Volume 12

Issue 11

World Journal of Cardiology

Contents

Monthly Volume 12 Number 11 November 26, 2020

ABOUT COVER
Editorial board member of World Journal of Cardiology, Dr. Alexander Kharlamov, MD, FESC (2018), FACC (2019),
FEACVI (2019), has 24 years of clinical experience in general cardiology (since 1996; Consultant Physician since
2007; Board-Certified Cardiologist since 2010), 19 years of translational research experience in nanomedicine and
biomedical engineering (since 2001), and about 13 years of bench-to-bedside study experience in interventional
cardiology (a leader of the research group since 2007), including investigations into advanced imaging, vascular
biology, and pathology, RTD of cardiovascular imaging software and medical devices (bioresorbable scaffolds and
stents). He is an author of more than 60 articles and grant proposals for the European Commission, and has
received various national and international awards for his research work. (L-Editor: Filipodia)

AIMS AND SCOPE
The primary aim of World Journal of Cardiology (WJC, World J Cardiol) is to provide scholars and readers from
various fields of cardiology with a platform to publish high-quality basic and clinical research articles and
communicate their research findings online.
WJC mainly publishes articles reporting research results and findings obtained in the field of cardiology and
covering a wide range of topics including acute coronary syndromes, aneurysm, angina, arrhythmias,
atherosclerosis, atrial fibrillation, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure,
hypertension, imaging, infection, myocardial infarction, pathology, peripheral vessels, public health, Raynaud’s
syndrome, stroke, thrombosis, and valvular disease.

INDEXING/ABSTRACTING
The WJC is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed
Central, Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal
Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ping Yan.

NAME OF JOURNAL

INSTRUCTIONS TO AUTHORS

World Journal of Cardiology

https://www.wjgnet.com/bpg/gerinfo/204

ISSN

GUIDELINES FOR ETHICS DOCUMENTS

ISSN 1949-8462 (online)

https://www.wjgnet.com/bpg/GerInfo/287

LAUNCH DATE

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

December 31, 2009

https://www.wjgnet.com/bpg/gerinfo/240

FREQUENCY

PUBLICATION ETHICS

Monthly

https://www.wjgnet.com/bpg/GerInfo/288

EDITORS-IN-CHIEF

PUBLICATION MISCONDUCT

Ramdas G Pai, Dimitrios Tousoulis, Marco Matteo Ciccone

https://www.wjgnet.com/bpg/gerinfo/208

EDITORIAL BOARD MEMBERS

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/1949-8462/editorialboard.htm

https://www.wjgnet.com/bpg/gerinfo/242

PUBLICATION DATE

STEPS FOR SUBMITTING MANUSCRIPTS

November 26, 2020

https://www.wjgnet.com/bpg/GerInfo/239

COPYRIGHT

ONLINE SUBMISSION

© 2020 Baishideng Publishing Group Inc

https://www.f6publishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

WJC

https://www.wjgnet.com

II

November 26, 2020

Volume 12

Issue 11

WJ C

World Journal of
Cardiology

Submit a Manuscript: https://www.f6publishing.com

World J Cardiol 2020 November 26; 12(11): 550-558

DOI: 10.4330/wjc.v12.i11.550

ISSN 1949-8462 (online)

META-ANALYSIS

Effects of left ventricular assist device on pulmonary functions and
pulmonary hemodynamics: A meta-analysis
Waqas Ullah, Casey Meizinger, Zain Ali, Ankur Panchal, Rehan Saeed, Donald C Haas, Eduardo Rame

ORCID number: Waqas Ullah 00000002-4850-0309; Casey Meizinger
0000-0001-7462-2468; Zain Ali 00000002-5457-9420; Ankur Panchal
0000-0002-5457-7877; Rehan Saeed
0000-0001-9099-4202; Donald C Haas
0000-0002-8644-4205; Eduardo Rame
0000-0002-2936-1702.

Author contributions: Ullah W
contributed to conceptualization,
analysis, and manuscript writing;
Meizinger C contributed to
manuscript writing and data
collection; Ali Z contributrd to
revision; Panchal A contributed to
data curation; Saeed R contributed
to editing; Haas DC and Rame E
contributed to supervision.

Conflict-of-interest statement: The
authors have no conflict of interest.

PRISMA 2009 Checklist statement:
The authors have read the PRISMA
2009 Checklist, and the manuscript
was prepared and revised
according to the PRISMA 2009
Checklist.

Waqas Ullah, Casey Meizinger, Zain Ali, Rehan Saeed, Department of Internal Medicine,
Abington Jefferson Health, Abington, PA 19001, United States
Ankur Panchal, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA
15213, United States
Donald C Haas, Department of Cardiology, Abington Jefferson Health, Abington, PA 19001,
United States
Eduardo Rame, Department of Cardiology, Thomas Jefferson University, Abington, PA 19001,
United States
Corresponding author: Waqas Ullah, MD, Doctor, Department of Internal Medicine, Abington
Jefferson Health, 1200 Old York Road, Abington, PA 19001, United States.
waqasullah.dr@gmail.com

Abstract
BACKGROUND
Given current evidence, the effect of left ventricular assist device (LVAD)
implantation on pulmonary function tests remains controversial.
AIM
To better understand the factors contributing to the changes seen on pulmonary
function testing and the correlation with pulmonary hemodynamics after LVAD
implantation.

Open-Access: This article is an

METHODS
Electronic databases were queried to identify relevant articles. The summary
effect size was estimated as a difference of overall means and standard deviation
on a random-effects model.

open-access article that was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution
NonCommercial (CC BY-NC 4.0)
license, which permits others to
distribute, remix, adapt, build

RESULTS
A total of four studies comprising 219 patients were included. The overall mean
forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and
diffusion lung capacity of carbon monoxide (DLCO) after LVAD implantation
were significantly lower by 0.23 L (95%CI: 0.11-0.34, P = 00002), 0.18 L (95%CI:
0.03-0.34, P = 0.02), and 3.16 mmol/min (95%CI: 2.17-4.14, P < 0.00001),
respectively. The net post-LVAD mean value of the cardiac index was
significantly higher by 0.49 L/min/m2 (95%CI: 0.31-0.66, P < 0.00001) compared to
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pre-LVAD value. The pulmonary capillary wedge pressure and pulmonary
vascular resistance were significantly reduced after LVAD implantation by 8.56
mmHg (95%CI: 3.78-13.35, P = 0.0004), and 0.83 Woods U (95%CI: 0.11-1.55, P =
0.02), respectively. There was no significant difference observed in the right atrial
pressure after LVAD implantation (0.61 mmHg, 95%CI: -2.00 to 3.32, P = 0.65).
Overall findings appear to be driven by studies using HeartMateII devices.
CONCLUSION
LVAD implantation might be associated with a significant reduction of the
spirometric measures, including FEV1, FVC, and DLCO, and an overall
improvement of pulmonary hemodynamics.

Specialty type: Cardiac and
cardiovascular systems

Country/Territory of origin: United
States

Key Words: Pulmonary function tests; Left ventricular assist device; Spirometry;
Ventricular assist device
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INTRODUCTION
Since the advent of the left ventricular assist device (LVAD) in 1988, literature has
appropriately focused on its survival benefits in heart failure patients[1,2]. Over the
years, with an increase in its use, many LVAD related complications also started
surfacing together. Arena et al[3] in 1999 were the first to present data, implicating a
decrease in spirometric measures in patients with LVAD implantation. These
observation was based on the comparison of pre and post-LVAD findings in a 58-year
old gentleman[3]. Later on, more observational studies attempted to elucidate the
complex interplay of pathophysiological dynamics between LVAD and pulmonary
system, but had conflicting findings[4-7]. Until recently, there has been no concrete
evidence in the form of a randomized controlled trial (RCT) or meta-analysis to
identify the net clinical benefit of LVAD in the context of worsened pulmonary
functions and improved pulmonary hemodynamics.

MATERIALS AND METHODS
Search strategy and study collection
A literature search was performed up to December 2019, using PubMed, EMBASE,
and Cochrane databases. There was no language or time restriction. The search
strategies included various combinations of medical subject headings (MeSH) to
generate two subsets of citations: One for LVAD and other for pulmonary function
tests (PFTs). The terms from the two subsets were combined in 1:1 combination using
boolean operators, and results from all possible combinations were screened for
relevant articles. Based on our research question, articles from the reference lists
pertinent to the clinical question were also evaluated by an independent author
(backward snow bowling). Studies comparing changes in PFTs and pulmonary
hemodynamics after LVAD implantation were included in the final analysis.
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Pulmonary hemodynamics included cardiac output (CO), right atrial pressure (RAP)
and pulmonary capillary wedge pressures (PCWP) assessment; pulmonary vascular
resistance (PVR) was calculated by the standard formula PVR = (mPAP - PCWP)/CO.
The studies with insufficient data, case reports, review articles, and conference papers
were excluded after detailed discussion (Figure 1).

Quality of included studies
The overall methodological quality of the included studies was low. Due to the
inclusion of single-center retrospective studies, the risk of selection bias could not be
assessed. Similarly, randomization and allocation concealment of the subjects at the
level of individual study could not be performed. Most studies, however, mentioned
the baseline characteristics of the included population except by Imamura et al[5]. The
risk of reporting bias across all studies was minimal due to adequate reporting of
outcomes. Only patients who had post-LVAD spirometry measurements were
included in the study, minimizing the risk of attrition bias. All included studies used a
self-control model in which the same population was assessed before and after an
intervention (LVAD implantation); hence, the risk for detection bias was negligible.
The detailed and summary bias graphs are given in Figure 2.

Statistical analysis
The statistical analysis was performed using the random-effects model (inverse
variance) to calculate the mean difference and SD for continuous variables. The
probability value of P < 0.05 was considered statistically significant. The “test for
overall effect” was reported as z value corroborating the inference from the 95%CI.
Higgins I-squared (I2) statistic model was used to assess variations in outcomes of the
included studies. I2 values of 50% or less corresponded to low to moderate, and 75% or
higher indicated large amounts of heterogeneity. Publication bias was illustrated
graphically using a funnel plot. The quality assessment of the included articles was
performed using the Cochrane guidelines for the systematic review and meta-analysis,
where each study was screened for five different types of bias (selection, performance,
detection, attrition, and reporting bias). All statistical analysis was performed using
the Cochrane Review Manager (RevMan) version 5.3.

RESULTS
Search results and study selection
The initial search on multiple databases revealed 1086 articles. After removal of
irrelevant and duplicate items, 132 articles deemed relevant for full-text review. We
further excluded 128 articles based on our selection criteria. Multiple attempts to
authors to retrieve data were unsuccessful. Four articles qualified for final analysis[4-7].
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram is shown in Figure 1.
A total of 219 patients, with a mean age of 54 ± 11 years, were included. About 73%
of the included subjects were males. Two thirds (74%) of the overall population had
2nd generation continuous flow devices (HeartMateII), while 26% of patients had a 3rd
generation pulsatile flow device (HeartWare). The overall mean basal metabolic index
was 26 ± 12 kg/m2. The mean left ventricular ejection fraction was 10%. The
indications for LVAD implantation were non-ischemic and ischemic cardiomyopathy
in 62% (136/219) and 36% (79/219) of patients, respectively. Sajgalik et al[6] were the
only ones reporting hypertrophic cardiomyopathy in four patients. The functional
status of the included population was defined either by a 6-min walk test (Raheja et al[7]
) or by classification of the New York Heart Association (NYHA) (Sajgalik et al[6]). The
mean brain nitric peptide level was 1695 pg/mL. Of the reported comorbidities,
diabetes, chronic kidney disease, and hypertension were the most common.
Approximately 22% (50/219) of the total population carried a diagnosis of chronic
obstructive lung disease (COPD). The mean follow-up duration and timing of postLVAD spirometry ranged from 6 mo to 12 mo. The detailed study characteristics are
given in Supplementary Table 1.

Pooled estimate of spirometric changes with LVAD implantation
The overall mean forced expiratory volume in one second (FEV1) and forced vital
capacity (FVC) values were significantly lower after LVAD implantation by 0.23 L
(95%CI: 0.11-0.34, P = 00002) and 0.18 L (95%CI: 0.03-0.34, P = 0.02), respectively. The
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Figure 1 PRISMA flow diagram of the included studies.

Figure 2 Detailed methodological quality and bias assessment of included studies.

heterogeneity among the outcomes of the included studies was minimal for both FEV1
and FVC with an I2 = 0% (P = 0.98 and P = 0.75, respectively) (Figure 3A and B). The
overall mean value of ΔDLCO (diffusion lung capacity of carbon monoxide) was
robustly reduced by 3.16 mmol/min (95%CI: 2.17-4.14, P < 0.00001) in the post-LVAD
state. There was no heterogeneity among the outcomes of individual studies I2 = 0% (P
= 0.59) (Figure 3C).

Pooled estimate of pulmonary hemodynamics with LVAD implantation
All indices of pulmonary hemodynamic observed an overall improvement with LVAD
implantation. The net post-LVAD implantation mean cardiac index was significantly
higher by 0.49 L/min/m2 (95%CI: 0.31-0.66, P < 0.00001) compared to pre-LVAD
values with no heterogeneity (I2 = 0). Imamura et al[5] study contributed more than half
to the overall effect size (52% weight) (Figure 4A). Compared to pre-LVAD values, the
pooled estimate of PCWP and PVR was significantly reduced after post-LVAD
implantation by 8.56 mmHg (95%CI: 3.78-13.35, P = 0.0004), and 0.83 Woods U (95%CI:
0.11-1.55, P = 0.02), respectively (Figure 4B and C). There was no significant difference
observed in RAP in the post-LVAD cohort both at the study level and in the pooled
analysis (0.61 mmHg, 95%CI: -2.00 to 3.32, P = 0.65). The heterogeneity among the
included studies was moderate (I2 = 76%, I2 = 42%, I2 = 57%, respectively) (Figure 4D).
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Figure 3 Forest plot depicting the pooled mean difference of forced expiratory volume in one second (A), forced vital capacity (B) and
diffusion lung capacity of carbon monoxide (C) between pre- and post-left ventricular assist device patients. FEV1: Forced expiratory volume
in one second; FVC: Forced vital capacity; DLCO: Diffusion lung capacity of carbon monoxide; LVAD: Left ventricular assist device.

DISCUSSION
Our meta-analysis shows a substantial decrease in the overall mean spirometric
measures (FEV1, FVC, FEV1/FVC, and DLCO) in post-LVAD patients. The pulmonary
hemodynamics were, however, significantly improved with an overall mean decrease
in the PCWP and PVR. As expected, post-LVAD patients observed a substantial
improvement in the cardiac index. Together these changes represented a net decrease
in left ventricular filling pressure and an improvement in the left ventricular function.
There was no effect seen on the net difference of RAP in patients following LVAD
implantation. The detailed pre- and post-LVAD spirometric metrics are given in
Figure 5.
Many factors could be accounted for the restrictive pulmonary pattern seen in postLVAD patients. The initial transient decline in PFTs (FVC and FEV1) could be
attributed to anesthesia effects or respiratory muscle weakness due to the major
cardiothoracic surgery[4]. Long term decrease in post-LVAD FVC can partly be
explained by an LVAD patient now having an object that occupies approximately 50
mL (HeartWare) to 63 mL (HeartMateII) of intrathoracic space[4]. In addition to the
anatomical limitations, a constellation of mechanical and physiological mechanisms
compromises the diaphragmatic functions, such as surgical implantation of
HeartMateII below the diaphragm, sternotomy, thoracic scaring and respiratory
muscle weakness due to cardiac cachexia[7]. Moreover, heart failure induced reactive
fibrosis, pleural effusion, and cardiomegaly can worsen the post-LVAD spirometric
measures by mechanically impeding the lungs from expanding[6]. Heart failure can
also incite bronchial hypersensitivity or can cause interstitial edema, and compressive
atelectasis, further compromising the spirometric metrics of post-LVAD patients. Some
post-LVAD patients are at high risk of decline in spirometric measures if they have a
compelling indication for pneumotoxic medications such as amiodarone[4-7].
The literature on the post-LVAD pulmonary dynamics is scarce. Our extensive
literature search identified four studies for quantitative analysis[4-7]. All these studies
unanimously agreed on the decline of pulmonary functions and the improvement of
pulmonary hemodynamics in post-LVAD patients. These studies, however, should be
interpreted in the context of its methodological limitations. Most studies used older
generation devices (HeartMateII), while more contemporary studies used the newer
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Figure 4 Forest plot showing pooled comparison of mean difference in cardiac index (A), pulmonary capillary wedge pressures (B),
pulmonary vascular resistance (C), and right atrial pressure (D) between pre- and post-left ventricular assist device groups. PCWP:
Pulmonary capillary wedge pressures; PVR: Pulmonary vascular resistance; RAP: Right atrial pressure; LVAD: Left ventricular assist device.

generation pulsatile LVAD devices (HeartWare). This potentially skewed the overall
results of the studies. Mohamedali et al[4] in 2015, were the first to recognize that a
decrease in the spirometric measures (FEV1, FVC, and DLCO) was actually driven by
the HeartMateII devices, rather than HeartWare. They attributed these findings to the
surgical resection related paralysis of the diaphragm, post-procedure lung fibrosis,
and restriction of the left hemidiaphragm by a relatively larger device size in the
former[4]. Raheja et al[7] subsequently validated the overall results of the prior study.
They also quantified the effect of LVAD on the functional status of heart failure
patients using a six-minute walk distance (MWD). A significant correlation between
the MWD and LVAD induced change in FEV1 (P = 0.0466), and DLCO (P = 0.0032)
was demonstrated; however, these findings were never adjusted for the duration of
follow up[7]. Sajgalik et al[6] hurdled these limitations by performing a stratified analysis
based on different follow-up durations. Although a substantial amount of decline in
FEV1 (P = 0.04) and FVC (P = 0.01) was observed at 12-mo, there was no significant
decrease in PFTs on a shorter follow-up duration of 6-mo (FVC P = 0.07, FEV1 P =
0.27). Similarly, the observed predictive effect of survival with the change of DLCO at
6-mo (P = 0.03) was attenuated at an extended follow-up duration of 12-mo (P =
0.22)[6].
Mohamedali et al[4] exclusively used the 2nd generation (HeartMateII) devices, while
about 77% LVADs in the Sajgalik et al[6] and 88% of devices used by Raheja et al[7] study
were HeartMateII devices. Despite a higher percentage of HeartMateII devices in the
later studies, the overall outcomes were never stratified based on the device type[5-7].
Therefore, a clear distinction between the relative safety of HeartMateII and
HeartWare could not be ascertained. This, along with the fact that all studies had
substantial limitations due to non-randomized data, call into question the
generalizability of individual results.
One can also argue that spirometric changes observed in post-LVAD patients could
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Figure 5 Trend of decrease in forced expiratory volume in one second (A), forced vital capacity (B), and diffusion lung capacity of carbon
monoxide (C) in the included studies. FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; DLCO: Diffusion lung capacity of carbon
monoxide; LVAD: Left ventricular assist device.

be a transient decline of the pre-existing lung disease, and might not have long-term
consequences. As claimed by Imamura et al[5] in his analysis, that the post-LVAD PFTs
worsening is a reversible phenomenon with heart transplantation. However, more
studies are needed to shed light on the long-term impacts of LVAD implantation on
pulmonary dynamics. It should also be noted that, approximately 36% of patients from
Sajgalik et al[6] study had obstructive sleep apnea, while 29% of patients in Mohamedali
et al[4], and 22% of Raheja et al[7] patients had COPD. It is unclear if the decrease of postLVAD spirometric measures in the mentioned cohorts was an actual device effect or
was merely worsening of their underlying lung condition.
Given apparent differences in the outcomes and significant effect of covariates on
the results, one should be cautious about the clinical interpretations of individual
results. This, along with the fact that previous small studies were either underpowered
to detect clinical outcomes, or had conflicting findings, prompted us to integrate the
findings of these studies.
In contrast to individual data, our meta-analysis provides strong evidence that
LVAD related beneficial effects outweigh its potential spirometric decline in heart
failure patients. A minimal mean decrease in post-LVAD measures of FEV1 and FCV
by only 0.23 L and 0.18 L respectively is massively offset by a significantly higher
increase in the cardiac index by 0.49 L/min/m2, and improvement of PCWP by 8.56
mmHg and PVR by 0.83 Woods U, respectively. Our meta-analysis also illustrates the
paucity of randomized data in post-LVAD patients and highlights the limits on our
ability to draw definitive conclusions due to the retrospective nature of data.
Our study is constrained by the limitations of the available data. A significant
barrier was our inability to perform a stratified subgroup analysis based on different
LVAD types and variable follow up durations. The inherent heterogeneity in the
inclusion criteria of studies could not be accounted for in the pooled analysis. This, in
addition to the biases and confounding factors inherent in observational nonrandomized studies, call for caution when interpreting the results of this metaanalysis.
To determine the actual effect of LVAD implantation on spirometric metrics, it is
imperative to account for all the confounding variables in a controlled population. One
way would be to determine the causation of lung findings on a prospective scale or
conduction of a RCT. This will enable the researchers not only to assess the risk of
post-LVAD spirometric changes but can also help in the identification of instantaneous
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event rates such as mortality and survival benefits.

CONCLUSION
LVAD implantation might be associated with worsening of FEV1, FVC, and DLCO in
post-LVAD patients. However, the overall benefits of LVAD in the context of
pulmonary hemodynamics outweigh the presumed harm to spirometric metrics.
More large scale studies are needed to validate our findings.

ARTICLE HIGHLIGHTS
Research background
Recent studies suggest that left ventricular assist device (LVAD) implantation has not
been associated with an improvement in pulmonary function tests. However, the
improvement seen in post-LVAD pulmonary hemodynamics outweighs the observed
decrease in spirometry.

Research motivation
The studies investigating these parameters are not expansive and the overall
methodological quality of the studies available is low. Further inquiry into the effects
of the LVAD implantation on pulmonary hemodynamics, objective pulmonary
function testing and on the observed clinical outcomes is needed.

Research objectives
This meta-analysis aims to stratify the observed outcomes in studies assessing these
parameters, in order to better understand the factors contributing to the changes seen
on pulmonary function testing and the correlation with pulmonary hemodynamics.

Research methods
Our study literature search was performed on published data until December 2019,
using PubMed, EMBASE, and Cochrane databases. After screening the studies 132
articles deemed relevant were reviewed. 128 articles were excluded based on our
selection criteria. Four studies were analysed and included in this meta-analysis.

Research results
A total of four studies comprising 219 patients were included. The overall mean forced
expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion
lung capacity of carbon monoxide (DLCO) after LVAD implantation were significantly
lower by 0.23 L (95%CI: 0.11-0.34, P = 00002), 0.18 L (95%CI: 0.03-0.34, P = 0.02), and
3.16 mmol/min (95%CI: 2.17-4.14, P < 0.00001), respectively. The pulmonary capillary
wedge pressure and pulmonary vascular resistance were significantly reduced after
LVAD implantation by 8.56 mmHg (95%CI: 3.78-13.35, P = 0.0004), and 0.83 Woods U
(95%CI: 0.11-1.55, P = 0.02), respectively. There was no significant difference observed
in the right atrial pressure after LVAD implantation (0.61 mmHg, 95%CI: -2.00 to 3.32,
P = 0.65).

Research conclusions
LVAD implantation might be associated with a significant reduction of the spirometric
measures, including FEV1, FVC, and DLCO, and an overall improvement of
pulmonary hemodynamics.

Research perspectives
The short term and long-term effects of LVAD on the pulmonary hemodynamics on
and pulmonary function tests need to be expanded and are essential in order to better
assess outcomes. The need for randomized control trials exists to identify confounding
factors that may affect the outcomes seen in the studies analyzed. Also, further studies
with extended follow-up are needed to assess the clinical outcomes of the changes
seen on PFTs and hemodynamics.
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